Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28525554 | 0.84 | LMNA (0.61) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL20176880 | 0.81 | LMNA (0.53) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL2313930 | 0.80 | MEN1 (0.55) | HPGDSALDH1A1SMN1; SMN2LTA4HHTT | |
| SCHEMBL18554989 | 0.79 | FFAR1 (0.40) | LMNAHPGDSALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL14820292 | 0.77 | LMNA (0.49) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL30535283 | 0.77 | LMNA (0.82) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL676142 | 0.77 | LMNA (0.82) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL788675 | 0.77 | LMNA (0.62) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL3978652 | 0.76 | GRM5 (0.35) | SMN1; SMN2GRM5 | |
| SCHEMBL8304733 | 0.76 | LMNA (0.66) | LMNATDP1CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009058937-A2 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | LMNA 3930/4885TDP1 3781/4885CYP11B1 146/4885 |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | LMNA 3930/4885TDP1 3781/4885CYP11B1 146/4885 |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | AHR, MALT1, ABL1 | LMNA 1994/4885TDP1 1490/4885CYP11B1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.